


**AMENDMENTS TO THE CLAIMS**

1. (Currently amended) A bicyclo derivative represented by the following general formula (1):



[wherein wherein R<sup>1</sup> is Mehydrogen atom, halogen atom, carboxyl group, C<sub>1</sub> to C<sub>4</sub> alkyl group which may be substituted with hydroxy group, or a substituted or unsubstituted aryl group; X is CH<sub>2</sub>, CHF, CF<sub>2</sub>, CHOH, S or O; and n is an integer of 1 to 3.] 3, or a pharmaceutically acceptable salt thereof.

- 2-5. (Cancelled)

6. (Currently amended) A pharmaceutical product containing as an active ingredient the bicyclo derivative of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable auxiliary agent.

7. (Cancelled)

8. (Currently amended) A therapeutic agent for method for treating a mammal having a disease involving DPP-IV containing as an active ingredient, which comprises administering a therapeutically effective amount of the bicyclo derivative of claim 1 or a pharmaceutically acceptable salt thereof to the mammal.

9. (Currently amended) The therapeutic agent method according to claim 8, wherein the disease involving DPP-IV is diabetes or associated diabetic complication.